The expression and clinical significance of Treg cells in chronic myelocytic leukemia

Regulatory T cell (Treg) can regulate auto-immune response. It counteracts against autogenic or allogenic tumor antigens, and maintains immune tolerance and cell homeostasis via inhibiting various physiological or pathological immune responses. Study has found that Treg cells could inhibit the function of immune effector cells with anti-tumor activity, and played important roles in the immune escape of tumor cells. This study analyzed the expression of Treg in Chronic Myelocytic Leukemia (CML), to discuss their effects on disease treatment efficacy as well as prognosis. A total of 107 CML patients were recruited. Flow cytometry was used to measure the peripheral level of CD4+CD25+Foxp3+ Treg. Using averaged antigen expression level as the cut-off line, patients were divided into high and low level groups, whose treatment efficacy and drug resistance were evaluated. Kaplan-Meier approach was used to plot patient survival curve for comparison of survival rates. CD4+CD25+Foxp3+ Treg was significantly higher in chronic untreated group 6.22 ± 1.88% and accelerative/excess blast group 6.79 ± 2.05% compared with control group 1.81 ± 0.84% or chronic treatment group 2.06 ± 1.13%, p<0.05 in all cases). Patients with high Treg levels had lower levels of 3mCHR (3-month complete hematological remission), 12mCCR (12-month complete cytogenetic remission) and 18mCMR (18-month complete molecular remission), but higher drug resistance level than patients with low Treg levels (p<0.05). Overall survival rate of high-Treg patients was remarkably lower than that in low-Treg group (χ2=4.569, p=0.035). Peripheral level of CD4+CD25+Foxp3+ Treg can affect CML course and prognosis, and has implications for the diagnosis and treatment.

[1]  D. Perrotti,et al.  Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay. , 2017, Current drug targets.

[2]  G. Lal,et al.  Regulatory and effector functions of gamma–delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer , 2016, International journal of cancer.

[3]  H. Nishikawa,et al.  Roles of regulatory T cells in cancer immunity. , 2016, International immunology.

[4]  R. Vento,et al.  The analysis of estrogen receptor-α positive breast cancer stem-like cells unveils a high expression of the serpin proteinase inhibitor PI-9: Possible regulatory mechanisms. , 2016, International journal of oncology.

[5]  W. Stock,et al.  Incorporating measurable (‘minimal’) residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia , 2016, Leukemia & lymphoma.

[6]  M. Breccia,et al.  How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety , 2016, Expert opinion on pharmacotherapy.

[7]  Mohamed A. M. Ali,et al.  Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy , 2016, Molecular Diagnosis & Therapy.

[8]  F. Housseau,et al.  Procarcinogenic regulatory T cells in microbial-induced colon cancer , 2016, Oncoimmunology.

[9]  F. Moassass,et al.  Correlation of p210 BCR-ABL transcript variants with clinical, parameters and disease outcome in 45 chronic myeloid leukemia patients. , 2016, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[10]  J. Hasford,et al.  Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV , 2016, Leukemia.

[11]  G. Saydam,et al.  Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era. , 2013, American journal of blood research.

[12]  A. Nagler,et al.  Regulatory T Cells in Allogeneic Stem Cell Transplantation , 2013, Clinical & developmental immunology.

[13]  J. Yi,et al.  T-Bet Mediated Anti-Neoplastic Effects of Dendritic Cell-Cytokine Induced Killer Cells in vitro , 2012, Iranian journal of pediatrics.

[14]  Hong Zhu,et al.  Immunophenotype and increased presence of CD4(+)CD25(+) regulatory T cells in patients with acute lymphoblastic leukemia. , 2012, Oncology letters.

[15]  Yi-xiang Han,et al.  Elevated frequencies of CD4+CD25+CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia , 2011, International journal of cancer.

[16]  B. Schilling,et al.  Dendritic cell generation and CD4+CD25HIGHFOXP3+ regulatory T cells in human head and neck carcinoma during Radio-chemotherapy , 2011, European journal of medical research.

[17]  A. Neubauer,et al.  Chronische myeloische Leukämie , 2011, Der Internist.

[18]  R. Clark,et al.  Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive. , 2010, Experimental hematology.

[19]  T. Giese,et al.  In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. , 2006, Blood.

[20]  Shiang Huang,et al.  Increased population of CD4+CD25high regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients , 2005, European journal of haematology.

[21]  R. Weissleder,et al.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo , 2005 .

[22]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[23]  M. Steurer,et al.  Increase of regulatory T cells in the peripheral blood of cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  J. Melo,et al.  The molecular biology of chronic myeloid leukemia. , 2000, Blood.

[25]  M. Karas,et al.  Prognostic factors to predict outcome of reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukemia. , 2016, Neoplasma.

[26]  F. Ravandi,et al.  Evolving Therapies in Acute Myeloid Leukemia: Progress at Last? , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[27]  L. Hansson,et al.  CD4+ regulatory T cells in gastric cancer mucosa are proliferating and express high levels of IL-10 but little TGF-β , 2015, Gastric Cancer.

[28]  R. Weissleder,et al.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.